• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Antitussive offers convenient twice-daily dosing


The FDA recently approved codeine/chlorpheniramine (Codeprex, Celltech Group) extended-release suspension (CIII) for the temporary relief of cough, as may occur with the common cold or inhaled irritants, and for the temporary relief of runny nose; sneezing; itching of the nose or throat; and itchy, watery eyes due to hay fever, other upper respiratory allergies, or allergic rhinitis. The product is expected to be available in retail pharmacies by the fourth quarter.

© 2023 MJH Life Sciences

All rights reserved.